The cardiac troponins form part of the regulatory mechanism~or muscle contraction. Specific cardiac isoforms of cardiac troponin T and cardiac troponin I exist and commercially available immun?~ssay systems .have be.en developed for their measurement. A large number of clinical and analytical studies have been performed and the measurement of cardiac troponins is now considered the 'gold standard' biochemical test for diagnosis of myocardial damage. Th~re have been advances in understanding the development and structure of troponms and their degradation following myocardial cell necrosis. This has .c~ntributed to the understanding of the problems with current assays. Greater clinical~se has also highlighted areas of analytical and clinical c~nfusion. T~e assays are reviewed b~~ed on manufacturers' information, current published material as well as the authors inhouse experience.
INTRODUCTION
Since the original description of the measurement of cardiac troponin T (cTnT) by Katus et al. in 1989' and subsequently of cardiac troponin I (cTnI>,2 there has been a revolution in the technology for cardiac marker measurement. The production of sensitive, specific assays for t~e cardiac troponins which can be used in real tIme has been a quantum leap for the laboratory. This has been accompanied by a range of landmark clinical studies that have resulted in defining cTn measurement) as the 'gold standard' test for acute myocardial infarction (AMI). The advantage of the cTn lies in their ability to provide a cardiospecific diagnosis and prognostic risk assessment and to guide therapy in patients adrnitted > with suspected acute coronary syndromes. This article discusses the biochemistry of the troponins and how this influences the analytical aspects of the currently available cTn assays, reviews the relevant pUblished analytical and clinical data for the current assays and summarizes the data available from manufacturers. 
Structure and function of cardiac troponins
The cTn form part of the cardiac contractile apparatus, the troponin-tropomyosin complex (see Fig. I ). This complex is found within the sarcomeres of all types of striated muscle but not in smooth muscle. A comprehensive account of the structure and sequences of the proteins is given by Dean." The troponin-tropornyosin complex acts to regulate muscular contraction and comprises three troponins [troponin C (TnC), 18 kDa; troponin I (TnI), 22 kDa; troponin T (TnT), 37 kDaJ plus tropomyosin. The complex resembles a tadpole, with the head comprising a dumb-bell-shaped TnC, a globular TnI and the C-terminal region of TnT; the tail is made up of the N-terminal region of TnT. The function of cTnT is structural, binding to tropomyosin and TnC. On depolarization of the sarcolemma, there is Ca 2 + release into the cytoplasm. The Ca2+ binds to TnC and induces a conformational change, which increases the affinity of TnC for TnI. TnI then moves away from the actin-tropomyosin complex. This results in release of the inhibition of actinomyosin ATPase, allowing ATP hydrolysis and muscle contraction. A single troponin-tropomyosin complex acts to inhibit seven actin monomers. As Ca 2 + is pumped back into the sarcoplasmic reticulum. the complex reverts to its previous conformation. inhibiting ATPase action and allowing muscle relaxation. Two sites located on the C-terminal domain of TnC bind both Ca2+ and Mg2+, but two Nterminal sites bind Ca2+ alone."? Tnl binds to actin, tropomyosin, TnT and TnC, for which it has two binding sites. The strength of the interaction between cTnI and TnC depends on the saturation of the TnC Ca2+-binding sites. s.6 • 8 Ann Clin Biochem 2001: 38 There are multiple sites for phosphorylation of cTnl, which acts to regulate Ca2+ sensitivity and actinomyosin ATPase activity. A cAMP-dependent protein kinase and a Ca 2 +-phospholipiddependent protein kinase (protein kinase C) phosphorylate cTnI at various sites. 9 • 10 Phosphorylation of Ser-23 and Ser-24 alters the conformation of the molecule affecting antibody bi di 11 ' m mg. It is not known if the phosphorylated or unphosphorylated form is present in the blood, TnC significantly affects the phosphorylation of TnI by different protein kinases.P Human cTnI contains two cysteine residues (Cys-80 and YS~97)13 and oxidation of the SH groups affects Its mteractions with other troponin compoent.s.14 Conversely, the reactivity of these groups IS dIfferent in purified TnI and in the whole troponin cornplex.Iv" The interaction between cTnT and cTnI and TnC is not as tight as that of the cTnI-TnC complex," TnT is not catalytic or regulatory but does act as a signal amplifier.
TnT and TnI each have three isoforms. These are found in cardiac muscle, fast twitch muscle and slow twitch muscle, respectively, and arẽ ncoded by individual genes. There is only one Isoform of TnC that is common to all types of mUscle. The cardiac isoforms of TnT, cTnT (chromosome Iq32) and cTnI (chromosome 19q13.3) have unique amino acid compositions and structures. There is sequence homology between cTnT and skeletal muscle TnT (sTnT). There are 125 differences between adult fast sTnT and cTnT (56,6% homology) and 120 differences between adult slow sTnT and cTnT (58,3% homology) . Similarly, there is sequence homology between cTnI and skeletal muscle TnI (sTnI). There are 123 amino acid sequence differences (41,4% homology) between adult fast sTnI and cTnI and 113 sequence differences (46'2% homology) between adult slow sTnI and cTnI. In both cases the sequence differences are concentrated in the N-terminal region, with cTnI having a unique N-terminal sequence. There is a cleavage site for endogenous proteases at residue 80 of cTnI.
It has been demonstrated that most of the cTnI sequence is antigenic, with the Nand Cterminal ends having the strongest antigenic regions." By using secondary structure prediction models, it is suggested that cTnI is not a globular protein but is linear with five ex-helices. Biophysical measurements suggest that cTnI has an extended conformation when complexed with cTnC. Figure 2 shows the amino acid sequence Troponin ontology A diversity of sTnT isoforms is possible by means of alternate splicing of mRNA transcripts. However, expression of exons appears to be tightly regulated and few variants are found as protein isoforms. During the development of foetal muscle there is simultaneous expression of isoforms from all three TnT genes. Foetal cTnT isoforms are transiently expressed'? but are not found in adult tissue. IS In human foetal skeletal muscle. a foetal isoform (TnTf) is predominantly expressed and the proportion of foetal cTnT is low. A human foetal exon with sequences similar to that of both adult fast sTnT and cTnT has been described. 19 Five cTnT isoforms are expressed in foetal cardiac muscle but sTnT is not expressed. In adult life, the TnT composition of the heart may change due to expression of different isoforms during heart failure. IS There is no expression of cTnl during development of foetal skeletal muscle. In the heart. slow sTnl is the dominant isoform during foetal development and in the neonatal period. During the first 9 months of life a transition from sTnl to cTnl occurs.l" The developmental changes in cTnT have lead to discussions of the possibility that there might be re-expression of cTnT in damaged or regenerating skeletal muscle. Studies in regenerating adult rat skeletal muscle following surgical or myotoxic injury found mRNA for cTnT and for fast and slow sTnT isoforrns, The proportions of sTnT isoforms did not vary according to muscle type and corresponded to the proportions seen in foetal skeletal muscle." An immunohistochemical study of adult rat slow skeletal muscle injured by freezing injury or denervation produced similar findings." However, during foetal development in the rat, cTnT makes up 30% of the total skeletal TnT, a different situation to that in humans. 17 • l s In an immunohistochemical study of normal and diseased skeletal human muscle, cTnT was detected in both muscle types." However, Western blot studies have not confirmed this finding and there have been no other reports of cTnT in normal muscle." 26 The antibody used (a polyclonal goat anti-cTn'T) was directed against N-terminal cTnT residues 3-15. which have a degree of sequence homology with cTnT and sTnT as well as with TnTf. Western blot Ann Clin Biochem 2001: 38 studies of skeletal muscle from patients with regenerating skeletal muscle showed the presence of cTnT.23 When these studies were performed using an antibody pair specific to adult cTnT, no isoforms corresponding to adult cTnT were detected." The presence of a human foetal exon with complete sequence homology to an exon in fast sTnT and cTnT may account for these findings.
TROPONINS IN RENAL FAILURE
It was originally reported that cTnT was elevated in renal failure but that cTnl was not detected." This was followed by reports that cTnT could be detected in the skeletal muscle of patients with end-stage renal disease (ESRD).23 Subsequent studies have clarified the position. The initial report of rhabdomyolysis and renal failure was complicated by assay performance of the first-generation cTnT assay.F' This is described more fully below. The second-generation assay using two cardiospecific antibodies has abolished this problem." With the use of realistic cut-offs and improvement in assay sensitivity, it has been shown that elevation of both cTnT and cTnl occurs in patients with ESRD.30 The proportion of patients with elevated cTnT is consistently greater (1875%) than the proportion of those with elevated cTnl (4-17%).3137 The probability of elevation is greatest in acute renal failure.:" In patients with chronic renal dysfunction, the greatest frequency of elevation is seen in ESRD patients receiving haemodialysis."
Reverse transcription polymerase chain reaction and Western blot analysis of skeletal muscle did not show cTnT mRNA or cTnT in muscle from ESRD patients." although there were reports of mRNA in a subsequent study." Repetition of the original study" with an antibody pair specific for adult cTnT did not detect cTnTY In a rat renal failure model, where cTnT would be expected to be present in regenerating skeletal muscle, cTnT could not be detected by Western blot or in muscle homogenatcs." Outcome studies have shown that the detection of cTnT and cTnl in the serum of patients with ESRD is accompanied by a worse prognosis." 44 although not all studies are consistent.tv" The presence of detectable cTnT and cTnl in ESRD is indicative of cardiac damage, but the mechanisms and clinical application remain to be clarified. 
PHYSICOCHEMICAL FACTORS AFFECTING ASSAY PERFORMANCE OF cTn METHODS

Distribution of cTn and kinetics of release and degradation
The content and distribution of cTnT and cTnJ c~mpared with other markers in the myocardium are shown in Table I . The majority of cTnT and cTnJ is found in the contractile apparatus and is released as a result of proteolytic degradation. Between 6% and 8% of cTnT and between 2·8% and 8·3% of cTnJ are found as a free cytosolic component.V"
The precise amount is not certain as studies have variously used either organ donors, postmortem tissue or atrial tissue. Disruption ?f intracellular contractile proteins as a result of Ischaemia occurs rapidly and this may produce the cytosolic pool. 53 Whether this cytosolic component is released into the extracellular compartment during ischaemia rather than following necrosis is a matter of debate." The release kinetics of cTnT are biphasic, with n initial early peak at 12h from onset of damage followed by a plateau phase lasting 48 h and a SUbsequent fall to undetectable levels by 10 days. The duration of elevation is determined by the size of the infarct; with small AMJs it may be as little as 7 days and with a large full-thickness AMI cTnT may be detectable at 21 days. The timing and magnitude of the early peak depend on whether successful reperfusion has occurred spontaneously or is due to thrombolytic therapy; SUccessful reperfusion results in an earlier, higher peak. 47 The release of cTnl is said to be monophasic with the lack of an earlier peak. ascribed to a smaller cytosolic pool of c'Tnl, although this is not consistent with apparently equivalent cytosolic fractions of cTnT and cTnJ. However, we have found in practice that there is a similar early rise in cTnl, although not of the same magnitude. This finding has been reported Measurement of cardiac troponins 427 by others." The duration of elevation is typically 5 days but again there is variation depending on infarct size.
Clearance
The clearance of cTnT and cTnl is not welt documented. The half-life of cTnT in the circulation is 120min,47 the prolonged window of detection being due to continuous release of cTnT from the myofibrillar pool as the contractile apparatus within the cell undergoes degradation. There are no data on the clearance of cTnl,
Release and degradation of cTnT and clnI
It has been shown, using gel filtration, that following AMI there is release of free cTnT and cTnT-eTnl-TnC (TIC) complex with some cTnT fragments. The initial release is of free cTnT with subsequent release of a mixture of TIC complex with a small amount of free cTnT. 56 In an elegant series of studies using 196 paired combinations of 15 monoclonal antibodies (MAbs) directed against different portions of the cTnl molecule, Katrukha et al. studied the release and degradation of cTnlY This approach showed that the dominant form of cTnl following AMI is in the cTnJ-TnC (lC) complex. The ratio between Ie complex and free cTnl varies following AMI. The maximal amount of free cTnl is present soon after AMI. The maximum concentration of total cTnl is 5-12 times that of free cTnl. This is also seen in gel filtration studies. 56 Other workers" have used three assay systems prepared for total c'Tnl, IC complex plus TIC complex and cTnI-~TnT (IT) complex plus TJC complex. They showed that there was little IT complex plus TIC complex. The majority of the cTnl was present as IC complex in patients with AMI and post cardioplegia. They considered that the majority of the cTnl released following myonecrosis is in the IC form.
Following release of TIC complex, it is probable that there is degradation into cTnT plus IC complex. Using serum from AMI patients and cardiac tissue extracts, Katrukha et al." were able to show that the N-and Cterminal regions of cTnl are vulnerable to proteolytic degradation. The most stable region was the central region of the molecule in the region of residues 30 110. This region has a Ca 2 I -dependent TnC-binding domain. In studies using recombinant cTnT, cTnl and TnC, other workers'" confirmed that the N-and Ctermini of the molecule are rapidly degraded, but suggested that the N-terminal region is relatively more stable and that this is not due to TnC complex formation. However, this study also showed that degradation of cTnI complexes is slower than that of free cTnI. These workers were only able to detect small numbers of proteolytic fragments using an antibody directed against residues 27-36. In this study, the residues in the N-terminal region that were stable were not fully identified.
IMPLICATIONS OF THE BASIC BIOCHEMISTRY OF cTnT AND cTnI FOR ASSA Y PERFORMANCE IN ROUTINE CLINICAL USE
Detailed comparative studies of assay performance have revealed marked differences in assay performance, particularly of cTnI assays. 56 The factors that affect routine performance of cTn assays are: developmental epitope expression and re-expression; assay calibration; sample requirements and matrix effects; epitope stability; differential recognition of epitopes and steric hindrance; and assay-specific false positives and false negatives.
Developmental epitope expression and re-expression
As cTnI is expressed only in myocardium, this marker theoretically offers the fewest problems. The early expression of sTnI rather than of cTnl in the myocardium makes cTnI measurement unsuitable for assessment of neonatal and perinatal cardiac damage. The possibility of reexpression of TnTf and other isoforms of cTnT has been discussed in detail above. There arc unique sequences in adult cTnT. The antibody selection in the current assay [M7 (recognizing residues 125131) and MIl. 7 (recognizing residues 136 147)] corresponds to cardiospecific sequences without sequence homology to TnTf. This is consistent with the finding of the cardiospecificity of the assay-" and the demonstration that elevations of cTnT and cTnl in renal failure represent true myocellular damage of prognostic significance.
As-llay calibration The information from manufacturers on assay calibrators is variable. When patients' samples arc compared across assays in which the manufacturers' standards or calibrators of free native or recombinant cTnl arc used, differences in cTnl levels arc more than IO-fold. Changing the cali brant to recombinant TIC complex or Ann Clin Biochem 2()(}I~38 TIC complex formed in vitro results in threefold differences in cTnI values." The optimal calibrator has been suggested to be TIC complex derived from cardiac tissue. In preparation of lyophilized material for external quality assessment, IC complex with added free cTnT gives optimal performance (Reid A, personal communication). Studies in which commercial assays have been re-calibrated using an external reference standard have demonstrated assay convergence, producing nearly equal cTnI values in AMI samples." It is therefore apparent that convergence on standardization will eliminate the majority of the methodological differences. With the consolidation of suppliers, this problem should be resolved. The Stratus, Opus and RxL systems are being calibrated to give comparable answers. The original calibration of the ACS: 180 system was equivalent to that of the Stratus II. Since both of these systems have good clinical outcome data, a pragmatic strategy would be for the manufacturers to recalibrate to provide assay equivalence with the Stratus, Opus and RxL systems (assuming the ACS: 180 and Centaur retain their equivalence) until such time as a reference preparation emerges that will give final standardization. This will allow sensible comparison of assays and assay performance and rational external quality assurance (EQA). The problems of standardization of troponin assays have been discussed in detail by Apple." Sample requirements and matrix effects Sample requirements for the different assays vary. The optimal sample material for the majority of systems would seem to be serum, but here problems can arise due to fibrin microclots or rnicroparticulates (usually lipoprotein aggregates). Fibrin microclots occur if the sample has not clotted adequately. This may arise if the patient is receiving heparin and the sample is taken through the same cannula. Microparticulates are a particular problem following freeze thaw cycles in some assay systems. Frozen samples need to be thoroughly mixed then aggressively centrifuged prior to analysis.
EDTA plasma can be used in a minority of assay systems. The effect of EDTA seems to be minimal in the cTnT assay but greater (and variable) in cTnl assays. The impact of EDTA is due to Ca 2 I sequestration and alteration of binding between TnC and cTnl. Addition of EDTA to serum samples from AMI patients followed by gel filtration shows alteration of the elution fraction. 56 This is discussed more fully below.
Heparin plasma was originally recommended for all cTn assays. In view of the recent NACBj IFCC recommendations 63, 64 this would be thẽ ptimal sample to pro~ide rapid turnaround time. Studies have shown that heparinized samples were unsuitable for analysis on the Access first-generation assay and this is not a recommended sample type. Differences between serum and plasma values are reported for a number of cTnI methods. The cTnI molecule is Positively charged (pI = 9,87) and can bind heparin, a negatively charged polyanion. This may reduce immunoreactivity either by causing conformational changes of the troponin mole-CUles or by directly covering analytical epitopes. 65 Recent work has shown a variable difference between cTnT and cTnI values from serum and heparinized plasma. 66, 67 This effect Was maximal in samples taken early following myonecrosis and it has been suggested that the effect is due to binding of heparin to free cTnT ?r. cTnJ. It has been recommended that hepar-Inized plasma should not be used for cTnT measurement. It is difficult to determine exactly what is the final heparin concentration in the current collection systems. 6S • 69 Our own studies av~not shown significant differences between hthlUm heparin plasma and serum samples. and th~re appears to be no problem in assay systems
USIng whole blood and calibrated on the basis of heparinized samples. Clearly, caution needs to be exercised if heparinized plasma is used and further investigations of this effect are required.
Stability to proteolysis and sample stability Sample instability is a dominant feature in assays that use widely spaced epitopes or if an unstable portion of the molecule has been selected. The current cTnT assay uses epitopes that are eight residues apart [M7 (recognizing residues 125131) and MIl.7 (recognizing residues 136 ·147)). The cTnT molecule appears to be very stable at room temperature. 4"C and frozen. Re-analysis of samples that have had long-term storage (up to 5 years at -70"C) shows no significant sample degradation and samples do not show significant changes in five freeze· thaw cycles.
For c'Tnl, the majority of assays have epitopes selected in the stable 30-110 region. This is certainly the case for the Stratus CS, RxL, Opus Plus (Dade-Behring, personal communication).
Jmmulite (DPC, personal communication). ACS: 180 (N-terminal region residues 27-39 and residues 70-87; Bayer Corporation. personal communication) and AxSYM (residues 87-91 and 20-39). 70 We obtained serum samples from patients with AMI and assayed for cTnT and cTnI. Serum was aliquoted into plain tubes and stored at room temperature for 24 h and at 4°C for 7 days and re-assayed. Aliquots were also stored at -20°C and -70 aC for 28 days and reassayed. Separate aliquots were also taken from the same fresh samples and subjected to five freeze-thaw cycles, cTnT and cTnI being assayed between each cycle. We have found excellent stability for the ACS: 180, lmmulite, Stratus CS and AxSYM assays." Epitope degradation has been a particular problem with the Access system due to the selection of a Cterminal epitope, and sample instability is marked/" Our own experience has been that a single freeze-thaw cycle is sufficient to substantially reduce the apparent cTnI level measured on the Access system.
DIFFERENTIAL RECOGNITION OF EPITOPES AND STERIC HINDRANCE
Effects of TnC
Studies on IC complex (constituted with a sixfold molar excess of TnC in the presence of 0·6 mmol Ca 2 t ) in normal human serum showed that the presence of TnC alters the apparent immunogenicity of c'Tnl. Comparison of detectable cTnI with or without added TnC resulted in either increases or decreases in the amount of measurable c'Tnl. This effect is Ca 2 t -dependent as it was found that addition of EDTA to the assay buffer could partially or totally reverse the effect." Studies of serum from AMI patients found that. depending on the antibody pair chosen, addition of EDTA to serum would have either no effect on apparent concentration or would result in an increased signal. This effect could be directly related to the effect of TnC on the assay system. with maximal effect in those systems that showed the greatest loss of signal in response to addition of TnC to free cTnI. Addition of EDT A reduces the magnitude of the interaction between the components of the IC complex. which may serve either to mask or to expose individual epitopes. This explains why EDTA plasma may not be suitable in all assay systems.
Redox and phosphorylation effects As discussed above, phosphorylation is part of the regulation of function of the troponintropomyosin complex and this results in conformational changes. I I Whether this occurs in vivo or has any impact on assay performance is unknown. There are also sites of potential oxidation of SH groups which induce conformational changes in vilro. 14 • 15 This is known to affect the performance of some of the commercially available assay systema"
ASSAY-SPECIFIC FALSE POSITIVES AND FALSE NEGATIVES
A number of assay-specific problems have been described. Interference from heterophile antibody and rheumatoid factor has been described for the AxSYM assay.P 75 Problems with fibrin clots have been reported for the Stratus" and AxSYM systems."
QUALITY ASSURANCE
Internal quality assurance Quality assurance material (a three-level Liquichek cardiac marker control and a low-level control, Liquichek cardiac marker control LT for low threshold) for cTnT and cTnl arc available from BioRad. These are supplied frozen as a liquid control with a 2-year shelflife when stored at -10 to -2()"C. II has a 10day life for cTnT and cTnl when thawed to and stored at 2 8"C. The manufacturers supply their own internal quality assessment (IQA) materials, some of which are manufacturer-specific (and do not actually contain any troponin).
External quality assurance External quality assessment (EQA) schemes are currently operated by the College of American Pathologists (CAP) and the Scottish External Quality Assessment Scheme (SEQAS).7K The distribution frequency of the CAP scheme is five samples every 4 months. SEQAS distributes three samples on a monthly basis. The SEQAS returns reflect the problems of assay calibration, with differences between methods. These differences arc not consistent, with some methods producing relatively different values at different cTnl concentrations. An EQA scheme is being developed by the Welsh External Quality Assessment Scheme.
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CARDIOSPECIFICITY OF TROPONIN MEASUREMENT,REFERENCE INTERVALS AND CLINICAL CUT-OFFS
The advent of cTn measurements has raised a number of issues affecting reference ranges, test evaluation and clinical cut-offs.
The background level of cTn in the circulation appears to be undetectable. In a study using a highly sensitive research assay with an analytical sensitivity of 0·003 jlgjL (3 ng/L), a background level for cTnl of 0'0175pgjL was obtained."? Reference population studies for cTnT and cTnI report the median value as undetectable and tend to report the 97·5th centile of the reference population as at, or more often below, the functional sensitivity of the assay. Progressive improvements in assay performance have successively lowered the detection limit and functional sensitivity. It would appear that the background level of cTnT and cTnl is effectively zero, or so low as to be (currently) undetectable. In a recent large-scale, multi-centre evaluation of the third-generation cTnT assay, over 1000 'normals' were studied and the 99th centile was found to be undetectable (zero signal). It is not practical to use zero as an upper reference limit. A value of 0'040'06jJgjL for cTnT may be a more pragmatic choice. For c'Tnl, a value of around 0·1 jlgjL is probably more appropriate.
On the basis of current data it would seem reasonable to expect methods to give an undetectable value or very low value as 'normal'. This is met by the majority of, but not all, assays. As assays are further improved it remains to be seen if a detectable value will be found.
The sensitivity and specificity levels of cTn measurements for myonecrosis have resulted in the detection of cardiac damage in a number of previously unsuspected clinical situations. This has resulted in the curdiospecificity of cTn measurements being questioned. Studies in patients with elevated creatine kinase (CK) and CK-MB isoenzyme of non-cardiac origin suffer from a problem due to the lack of a 'gold standard' technique to detect myocardial damage by other techniques such as imaging. An evaluation of the first-generation cTnT method in Marine commandos undcrgoing arduous physical training (as a model of 'pure' museuloskclctal injury without concomitant cardiac disease) found that cTnT values were below the diagnostic discriminant despite substantial elevations of CK and CK_MB. K O Repeating these studies and extending them to trained athletes undergoing physical activity known to induce CK and CK-MB release from skeletal muscle confirmed undetectable cTnT and cTnI despitẽ levations of CK and CK-MB. 81 However, even
In athletes, detectable cTnT and cTnI have been reported in association with evidence of reversible cardiac dysfunction." The data from stud~es in athletes support the concept of cardlOspecificity of cTn measurements. There are.~wo important findings that confirm the vahdlty of cTn measurements as true markers of cardiac damage. First, unanticipated elevation of cTnI in the patient population of an intensive care unit was associated with an adverse prognosis. 83 Second, correlation of the histopathological findings with biochemistry results showed that elevated cTn values can be directly related to evidence of cardiac myonecrosis.r':" The presence of elevated cTnT and/or cTnI in an appropriately validated assay can therefore be considered pathognomonic of myocardial damage.
Clinical evaluations of cTn methods and clinical cut-offs for the assay have required a reappraisal of the role of cardiac markers. Initial clinical evaluations of the assays yielded apparent specificity for diagnosis of AMI of less than 100%, with values as low as 46%86 being re.corded. This is clearly difficult to reconcile with a supposedly cardiospecific test. In other studies, the use of arbitrarily high cut-offs to produce a high specificity overlooked the data from reference range populations. Much of the problem with these studies comes from the selection of the diagnostic criteria for AMI in non-AMI populations with unstable angina. Reliance is placed on CK-MB mllss as the 'gold standard' against which all other tests are evaluated. The classification of patients positive for AMI becomes circular. AMI is diagnosed When CK-MB mllss is elevated, making CK-MBmll" measurement by definition 100% sensitive and specific and all other tests less 'accurute'. Conversely, minor elevations of CK-MB that fail to reach the diagnostic threshold for AMI are well described and associated with a Poor prognosis. 87.88 That these patients should show cTn elevations would be expected. The finding that elevations of cTnT8~~2 and cTnl~)~6 are related to an adverse prognosis'" has lead to the realization that cTn measurements can be considered as surrogate markers for plaque rupture. The sequence of events is plaque rupture with intraplaque haemorrhage followed by formation of an unstable platelet aggregate on the plaque. There are two possible subsequent developments. There may be plaque healing or there may be progressive platelet aggregation and fragmentation to produce platelet emboli that produce downstream micro-infarctions.":"
The suggestion has been made that there should be two clinical cut-offs, one for AMI and a second for high-risk unstable angina. Although having the appeal of apparent logic, this does not reflect either pathophysiology or modern medical management of patients with acute coronary syndromes (ACS). The patient with high-risk unstable angina has a worse prognosis than the patient presenting with ST segment elevation and AMI and has an equivalent prognosis to that of non-Q-wave AMI. Furthermore, it has been shown that there is a gradient of risk with cTn elevation: the greater the elevation, the greater the risk. 93.99.loo Joint discussions between the European and American Cardiac societies have produced recommendations that there should be a redefinition of AMI with cTn measurement becoming the new 'gold standard' for diagnosis of AMI. This is not such a revolutionary concept as it would appear. The diagnosis of non-Q wave AMI originated when it became apparent by aspartate transaminase (AST) measurements that there were patients without classical ECG changes who clearly had undergone myocardial infarction. The advent of measurement of CK, then CK-MB, served to extend the population classified as non-Q AMI. The definition of AMI has been based on a CK-MB level that is more than twice the upper reference limit. 101.102 It is therefore only a simple extension of this diagnostic classification to move to cTn in the same way that CK-MB superseded CK and AST. The consensus document from the European and American Cardiac Societies defines an increased value for cTn as a measurement exceeding the 99th percentile of a reference population.' Performance criteria for troponin assays are also defined, with acceptable imprecision at the 99th percentile being < 10%..' This removes the need for two cut-off values and produces a classification that reflects current management practice (Table 2) . Patients are divided into three categories. The first category is patients with ST segment elevation with elevated c'Tn, corresponding to the conventional diagnosis of AMI. The second category is patients without ST segment elevation with elevated cTn, corresponding to current non-Q AMI but extending this to include the 33% of patients with unstable angina who have detectable cTn. The final category will be patients without ST segment elevation or detectable cTn. This final group will include those with and without ECG abnormalities. They require further investigation to confirm or exclude ischaemic heart disease (lHD). The presence of changes such as ST segment depression on the ECG indicates a patient at high risk. The combination of the resting ECG with cTn status allows risk stratification 99 • loo (see Table 3 ). The absence of detectable cTn excludes a currently active unstable plaque but does not exclude IHD and does not exclude a flow-limiting stenosis. However, the combination of cTn and stress ECG can be used for effective risk straufication.I'"
Individual assay platforms and clinical evaluation data Individual assay characteristics are summarized in Table 4 ; these are based on information supplied by the manufacturers. Particular aspects of assay performance and published data, including analytical, epitope selection and clinical evaluations, are considered below.
CARDIAC TROPONIN T
Assay development
The first-generation methodology for cTnT used an enzyme-linked immunosorbent assay (ELI-SA) with two MAbs: the capture antibody conjugated to biotin (M7) and the detection antibody conjugated to peroxidase (lBIO). 24 Initially, the assay was evaluated on the ES22 system.'?' It was then automated and evaluated on the ES300 system as the ELISA for TnT.I05 This represented the first fully automated assay for cTn (first-generation assay).
This assay had two problems: one due to the assay formulation, the other due to the platform. The capture antibody in the initial formulation was completely cardiac-specific with <0·5% cross-reaction to skeletal muscle. The detection antibody, however, was only 78% cardiacspecific. This was not considered to be a problem. It was anticipated that complete removal of unbound troponin would have occurred at the washing step. before measurement. This was not the case. In rhabdomyolysis, an apparent 'false positive' cTnT value could be detected in patients with high CK values. This ~cTnT' d~sappeared on serial dilution of samples rom patients with rhabdomyolysis but not from samples from patients with AMI. 29 In the presence of high sTnT values encountered in rhabdomyolysis there is adherence of sTnT to the tube wall. This was incompletely removed by the washing step and detected by the second cross-reacting antibody. It is interesting to note that, in the original description, elevation of cTnT was detected in patients with skeletal mus~le damage. Experimentally, when the cardlOspecific MAb was used as the detection antibody rather than as the capture antibody, non-specific binding of sTnT was abolished."
The second problem was that the ES300 system Was a batch analyser with a 90-min cycle. In real terms this produced a 2-h turn-around time (~~T) with assays run daily, inadequate for chmcal use.
Introduction of the second-generation system overcame the assay formulation problem by use of completely cardiac-specific antibodies. The M7 MAb (125) (126) (127) (128) (129) (130) (131) was now used for detection and the MI1.7 MAb (136-147) was biotinylated and used for capture as the ENZYMUN test for TnT. This is completely cardiospecific and Shows no cross-reaction, detecting all forms of cTnT and giving equivalent results to the ELISA.25.33 The assay time was reduced to 45 min but still was a batch assay on the ES300/700 systems. This assay has subsequently been transferred to a random access analyser Using electrochemiluminescence immunoassay (ECLIA) technology. The M 11.7 MAb is used for capture and M7 MAb for detection in the Elecsys series (Elecsys 1010 and 2010), providing a 9-or 18-min TAT with improved sensitivity. This assay is equivalent to the second-generation assay.I06.107.108 The assay has been recently retandardized using human recombinant cTnT to Improve assay linearity (third-generation assay). This assay is equivalent to the second-generation assay in the range 0 -0·2 jlg/L but thereafter gives lower values. 1( 1 ) This means that clinical stUdies on risk stratification that have used discriminants in the range (}{)'2 jlg/L remain valid for the new assay. In use, estimates of assay percentage coefficient of variation (%CV) are 1'8-7,2. 10.108 In a multi-centre evaluation of the Elecsys 1010 (44 hospitals in 13 countries) with target values for assay %CV of 5·5 at 0·15 jlg/L and 5·0 at 6'0 jlg/L. we found 8H% of laboratories achieved this value and 97% of participants achieved a total imprecision of less than 10%. In our Point-of-care and whole-blood rapid assay formats The initial formulation of the rapid assay for cTnT was based on gold-labelled optically read immunoassay (GLORIA) technology. This is summarized in Fig. 3 . In this formulation (TROPTcW), the MAbs were M7~gold and 1810 biotin (the same antibodies as in the ELISA for TnT but switched). The assay was sold during 1994--1995, but only in some countries. The initial version had a reliable detection limit of 0·2-0·31lg/L; hence it required enhancement for use in risk stratification."9.120 A second-generation assay was then produced using the same antibodies with enhanced sensitivity, with a cut-off of 0·2 jlg/L; this was sold worldwide from 1995 as TROPT,wYI,I22 The third-generation system used the same antibodies as in Enzymun-Test for TnT but switched with M 11.7--gold (detection) and M7biotin (capture). This has been sold worldwide since 1996 as TROPT Sensitive~~123.124 and subsequently made quantitative by the use of the cardiac reader system (TROPT Quantita-tive~). 125 The current version has been recalibra ted using recombinant human cTnT as a standard. The detection limit of the assay is 0·05 [J.g/L with 100% sensitivity to detect a value of 0·1 [J.g /L. The assay can be read quantitatively with the cardiac reader to give an effective range of (} 
CARDIAC TROPONIN I
There is a range of platforms for cTnl covering core laboratory, urgent laboratory and point-ofcare testing (POCT) formats. Clinical evaluation of cTnl has been less comprehensive and coherent than that of cTnT. This is because cTnl has been available for less time and the diversity of platforms means that assays must be evaluated individually. Findings for one cTnl assay cannot be extrapolated to another unless the assays are calibrated to give equivalent results and have comparable analytical performance at the same clinical decision levels.
Abbott Diagnostics (AxSYM)
This assay was originally reported as a prototype system using a sheep polyclonal capture antibody and a mouse monoclonal detection antibody.P? The assay finally released for the AxSYM used an MAb specific for an epitope in the mid-portion of the cTnl primary structure (residues 87-91; cell line 8E1O; HyTest) and a peptide affinity-purified goat polyclonal antibody specific for residues 2(}""39 (Bio Pacific), hence a stable portion of the molecule. The assay is considered to have equal affinity for free and complexed forms of cTnl in the test environmerit,"? although this was found not to be the case using clinical samples. 56 In our own study of 242 normal subjects we found the 97·5th centile to be 0·59 [J.g/L and the 99th centile 1·7Jlg/L. We had previously noted elevated cTnI values using this method, which were not confirmed by cTnT or cTnI measurement on other systems. In the Marine commandos . arduous physical training group, we obtamed detectable cTnI in 30/79 (40%) with 3/79~4%) having values~I jlg/L. Spurious elevations of cTnI have been reported by others. 130.131 In particular, Heeschen and Hamm 131 noted 1·9% of patients had discordance between paired samples of serum and plasma, with differences in cTnI up to 5·1 jlg/L. The most probable explanation was microclots?" and therefore plasma would seem to be essential for this assay. If serum is used, it is essential that any positive value obtained is confirmed either with a repeat sample or by measurement of another cardiac marker.
Interference from rheumatoid factor has been d~umented for the AxSYM assay,7275 although this appears to have been substantially improved. 132 The clinical cut-off for AMI was estimated by receiver-operating characteristic (ROC) analysis to be 2 jlg/L. 128 There have been no outcome studies in patients with unstable angina although the role of cTni measured on the AxSYM has been examined with reference to I~b/lIla therapy. Here, a cut-off of~I jlg/L dIfferentiates those who will respond from those who will not. 133 In a study of 100 patients, we were able to use the AxSYM cTnI for risk stratification at I year but only at a diagnostic cu.t-off of 2 jlg/L.134 Further work is required in thiS area.
Bayer
There are two platforms: the lmmuno I (Bayer) and the ACS:180/Centaur (Bayer-Chiron),
lrnrnuno ,
The total assay O/OCY for the Immuno I has been reported as 4·4 (2,3 jlg/L), 1·6 (6,27 jlg/L) and 1·8 (44·35 jl8/L).36 The between-run imprecision is reported as 1·2% (2,5 Jlg/L) to 3·2% (34'0 jlg/ l)37 and II % (0'2 jlg/L), 4·9% (1·7 jlg/L), 2·8% (7'1 jlg/L) and 2·8% (49,9 jlg/L).1J5 The functional sensitivity of the assay has been reported as 0'15jl8/L (%CY=20)36 or <0·1 jlg/L,36 with an upper reference limit of 0·1 jlg/L35 or 0·3 Jlg/ L,37 The method has been clinicaIly evaluated!" in a substudy of the Thrombolysis In Myocardial Infarction (TIMl) liB cohort in 681 patients admitted with ECG evidence of ischaemia or biochemical evidence of infarction without ST segment elevation. Samples were
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obtained at baseline and/or 12-24 h from admission. Elevation of cTnI on admission or at any time in the first 24 h was associated with a significantly increased risk of a major adverse cardiac event (MACE: death, urgent revascularization or AMI) at 43 days from enrolment. Elevated admission cTnI (n = 322) was associated with a relative risk (RR) of 2·2 (1'3-3'6) for death or AMI. Any elevation in the first 24 h was associated with a significantly increased RR of AMI (2'3), death or AMI (2'0) and MACE (1'8). In the unstable angina subgroup (n = 345), elevation of cTnI at any point within the first 24 h from admission was associated with a significantly increased risk of AMI or MACE at 43 days but not of death. The limitation of the study is that the population represents a highly selected cohort of patients with unstable angina and non-Q AMI rather than a typical case-mix of patients admitted with chest pain.
ACS:J80/Centaur
The total %CY for the ACS:180 is reported as 8·3 (1'1 jlg/L), 9·4 (16,1 jlg/L) and 8·7 (34,1 jlg/ L). 135 We have found the precision to be 3·0% (2·3jlg/L), 2·9% (8'5jlg/L), 3·9% (l5'2jlg/L) and 2-8% (3'2jlg/L), 4·1% (I 3'6 jlg/L), 5-9% (39'3 jlg/L) across two kit lots. The detection limit of the assay is said to be 0·1 jlg/L and we have found reportable results to 0·05 jlg/L. In samples from Marine commandos, cTnI was undetectable in 72/88 and all values were below 0·5 jlg/L. 95 In the TlMI lIB cohort (n = 322), again cTnl elevation on admission was associated with an RR of 2·8 (95% CI: 1,5-5'1) for death or AMI. Any elevation in the first 24 h was associated with a significantly increased RR of AMI (3'5), death or AMI and MACE (2'1).
In the unstable angina subgroup (n = 345), elevation of cTnI at any point within the first 24h from admission was associated with a significantly increased risk of death, AMI or MACE at 43 days. In our own data, we examined 6-month event rates in 97 unselected sequential patients with unstable angina admitted to the coronary care unit and found that cTnI~0·1 jlg/L predicted an increased risk of death, AMI or re-admission with unstable angina (RR 1'9).95
Dade-Behring
There are three platforms that have undergone evaluation for routine clinical use: the Stratus, the Opus and the Dimension RxL.
Stratus
The Stratus assay has undergone extensive development and evaluation. The original cTnI assay! was a microtitre plate ELISA and had an imprecision from 21·0% (7·3ttg/L) to 15·5% (95' 3ttg/L) with a detection limit of 1·9ttg/L. There was no cross-reaction with sTnI and cTnI was not detectable in cases with skeletal muscle injury. This assay was transferred to the Baxter Stratus with a detection limit of 1·5ttg/L and upper reference limit of 3·I ttg/L. 136 • m Using these cut-off values, high specificity was found for the assay. In a study of 91 patients with unstable angina, elevation above 3·lttg/L at any point throughout the first 16h from admission was associated with a significant risk (RR 2,7) of death or AMI. 94 The assay was subsequently improved on the Stratus II, with the detection limit of the assay reduced to O' 35ttg/L with %CV of the assay of 13-3 (within-run) and 16·0 (between-run) at this level." The assay %CV has been reported as 15 (0,7 ttg/L) to 7 (2,0 ttg/L) 138 and 14 (0·8ttg/L) to 7·4 (2·5ttg/L).139 In this study the detection limit was reported as 0'5ttg/ L with a functional sensitivity of 0·8ttg/L. D9 The Stratus II was used in an analysis of samples from the TIMI IIIB clinical study. cTnI was measured on enrolment (effectively on or soon after hospital admission) in 1404 patients admitted with unstable angina or non-Q AMI, of whom 68·2% (948/1404) showed no elevation of CK-MB within the first 12h. 93 There was a significant increase in 42-day mortality in patients with cTnI~O'4ttg/L, most marked in patients enrolled 6--24 h from pain onset. Multivariate analysis confirmed this finding, with a significant increase in risk for each increase of lttg/L of cTnI. Again, this correlation was stronger in patients presenting more than 6 h from onset of chest pain. These findings were confirmed in a substudy of 770 patients from the Global Use of Strategies To Open occluded coronary arteries (GUSTO) I1a trial, although on a logistic regression model this study suggested greater sensitivity for cTnT than for cTnI. 1J8 The Stratus CS has superseded the Stratus II. The reported %CV is 4·5 (O·lttg/L) to 6·5 (0·82ttg/L) for plasma pools!" and 14·0 for a plasma pool of 0·08 Jlg/L, 5·0 (0'6 Jlg/L) and 8·1 (21·3ttg/L) for controls.v'" We have found the imprecision to be 6·3% (0·45ttg/L) to 1·75% (l8ttg/L), detection limit 0·01-.()·02ttg/L, functional sensitivity 0·03ttg/L and an upper reference limit of Q·08ttg/L. 139 ,\ 40 Ann Clin Biochem 2001: 38
Opus Plus
The reported assay %CV for the Opus is 12 (3-9ttg/L) to 9 (94'4ttg/L)141 and 13 (3,7 ttg/L) to 5·6 (84·9ttg/L). 142 We have found the %CV to vary from 6·7 (4·2ttg/L) to 3·2 (77-7ttg/L). The detection limit of the assay is consistently <0'5ttg/L, with cTnI undetectable in normal healthy individuals. AMI cut-off was found to be 2·5ttg/L, with no elevation when there was skeletal muscle trauma. 141, 142 In 516 patients admitted with non-ST segment elevation ACS, elevated cTnI at a cut-off of 2·0 p.g/L in the first 6 h following admission predicted 30-day risk of death but not AMI. In a subset of 309 with a final diagnosis of unstable angina, elevated cTnI at a cut-off of 2·0 ttg/L in the first 6 h following admission similarly predicted 30-day risk of cardiac death or AMI.I43 We have obtained similar findings.l'" An updated method for this assay has been released. Preliminary findings show imprecision of JO·9% (0'43ttg/L ) to 6·3% (l3·6ttg/L) using BioRad controls (NCCLS protocol).
Dimension RxL
The %CV for this method is reported as 8·8 (0,57 ttg/L) to 1·5 (l2·22ttg/L) with minimum detection limit of 0·04ttg/L and 97·5th centile in a healthy population of O·lttg/L. In the TIMI II B cohort, again, elevated admission cTnI (n = 322) was associated with an RR of 3·0 (1'5-5'7) for death or AMI and any elevation in the first 24 h with a significantly increased RR of AMI (4'5), death or AMI (3'2) and MACE (2'4).
In the unstable angina subgroup (n =345), elevation of cTnI at any point within the first 24 h from admission was associated with a significantly increased risk of death, AMI or MACE at 43 days.!" Diagnostic Products Corporation (lmmullte) There are two formulations available for the DPC assay: the standard cTnI and the Turbo assay. We have performed a preliminary evaluation of the routine assay. The %CV was 2·8 (l·96ttg/L) to 1·4 (21·3ttg/L) and the diagnostic cut-off by ROC analysis in a population admitted with unstable angina and non-Q AMI was 1·0ttg/L. All values in the non-cardiac population were less than 1·0ttg/L. For the Turbo assay, the %CV was 6·3 (3'Ottg/L) to 3·6 (l66·2ttg/L). In Marine commandos with elevated CK and CK-MB and in 200 normal healthy blood donors, cTnl was undetectable. When the Immulite cTnI assay was compared with the Stratus assay, excellent clinical concordance was achieved in distinguishing ACS patients from those with non-cardiac chest pain. 145
Sanofi-Pasteur/Beckman (Access) ollowing preliminary development and validation, this assay was produced as an enzyme Immunometric assay (EIA). Initial precision was reported as 26·7% (O'2Ilg/L) to 2·9% ( 20llg/L) and detection limit O·2Ilg/L. 146 There was no detectable cTnI in normals and no crossreaction with skeletal cTnI. 51 The assay was SUbsequently improved to give an analytical sensitivity of O'03Ilg/L and detection limit of O· J Ilg/L with %CV of 8 (O'lllg/L) to 8 (2Ilg/ l).55 Clinical evaluation of the assay showed g~od comparable performance with CK-MB, With elevation in some patients with unstable angina and no elevation in skeletal muscle trauma 51.55 or exercise-induced muscle damage.!' The assay was subsequently automated using the Access. Assay %CV is reported as 13'5 (O'19Ilg/ L) to 6'0 (28'6 Jig/L) with analytical sensitivity 0'007 Ilg/L and detection limit 0·046Ilg/L. The 97'5th centile was 0·03Ilg/L in a reference population (n = 61) with a diagnostic discriminant for AMI by ROC curve analysis of 0'15Ilg/ L.147 Comparison with cTnT showed diagnostic equivalence for AMI but more patients with unstable angina had elevated cTnT. 14K The major problem with the assay is sample stability6() and a new formulation has recently been produced.149
Ortho Diagnostics (Vitros sen
The reported %CV for this assay is 10 (0'35Ilg/ ) to 3·2 (15·5Ilg/L) with an analytical sensitivity of 0-0l8llg/L and a detection limit of 0-35 /-Ig/ L. The 97·5th centile of a normal population (n '= 200) was 0'1 /-Ig/L (serum) and 0·08/-1g/L (plasma) with an AMI diagnostic cut-off by ROC Curve analysis of 0·8 Jtg/U50
POCT SYSTEMS FOR CARDIAC TROPONINS
These can be divided into two categories: dedicated quantitative or qualitative devices ('stick tests') orientated primarily towards POCT; and rapid whole-blood analytical systems suitable for POCT or emergency laboratory use.
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Dedicated quantitative or qualitative devices ('stick tests') orientated primarily towards POCT There are three well-validated systems on the market.
TropT (Roche) This system has been described fully above. 157 The device has also been retrospectively evaluated for risk stratification in the emergency department in 773 consecutive patients who had had acute chest pain for less than 12 h without ST segment elevation. TnI status (positive or negative) was determined at least twice by POCT on arrival and 4 h or more later so that one sample was taken at least 6 h after the onset of pain. At 30-day follow-up, the event rate in patients with negative tests was 0,3%.155 The assay is now combined with CK-MB and myoglobin as a three-marker system.
Triage (Biositel Axis-Shield)
This device uses slightly different technology. Whole blood or plasma is added to a disposable test strip, which is then loaded into a meter. The strip contains a filter that allows plasma alone to enter the reaction and reading zone of the strip. Fluid flow is driven by capillary action and controlled by a defined surface architecture. Fluid enters the reaction area and interacts with fluorescent antibody conjugates to myoglobin, CK-MB and cTnI. The reaction mixture flows along the device detection lane. Analyteconjugate complexes are captured by immobilized antibodies on discrete analyte-specific zones and detected by fluorescence. The device includes a calibration-check test strip. Assay %CV is reported as 12 at 0·4 J1.g/L with the decision threshold for AMI of 0·4 J1.g/L by ROC curve analysis. The device was considered equivalent to conventional laboratory testing for diagnosis of AMI.15K
Rapid whole-blood analytical systems suitable for POeT or emergency laboratory use These are fully quantitative dedicated analysers using whole blood as sample matrix. There are two systems currently available.
A/Ill Clin Biochem 2()()I: 38
Stratus CS (Dade-Behring) The Stratus CS is primarily designed for use on heparinized whole blood but can be used for measurement of cTnI in plasma or serum samples. Blood is taken into a compatible primary sample tube containing heparin as anticoagulant. The tube is loaded into a sample handling assembly, which is inserted into the machine. The machine then transfers whole blood from this assembly to a disposable centrifugal rotor. The centrifugal rotor contains an inert barrier material with a density between that of plasma and blood cells. During centrifugation on board the instrument, the inert material rises to the plasma-cell interface aM forms a barrier to separate plasma from red cells prior to analysis. Plasma is used as the sample matrix. Assay characteristics for plasma have been described previously. Samples are stable for up to 2 h at room temperature in whole blood. Of 121 patients with unstable angina, 45% had cTnI~0'08 Jl.g/L within 4 h from arrival, with a 30-day event rate (death or AMI) of 25·9% compared with 1·5% in the cTnl-negative group. 139 Alpha Dx (Sigma Diagnostics) This is one of the most interesting and innovative systems recently developed that uses whole blood anticoagulated with potassium-EDTA as the sample for measurement of cTnI.
The system comprises a portable, integrated immunoassay analyser, fluid cassette and reagent system. The fluid cassette contains a stabilized, buffered detergent solution that is used both for the rehydration of dried reagent and for protocol washes. Reagents are supplied in the form of test disks, each of which contains all the required test-specific reagents together with bi-Ievel quality controls for each test in stabilized form. A diskette contains lot-specific calibration information, limits for system quality control and expiry date for each lot. The test rotor consists of three geometrically equivalent segments in a radial design. There is one for the test sample, one for a high and one for a low quality control. The test process is initiated by dispensing wash/buffer fluid into the sample and control chambers of the test disk to rehydrate the reagents and controls. A precise volume of sample is transferred to the sample chamber.
Spinning the test disk transfers the reaction mixture and is used for wash steps. Within the reaction chamber, there is a sandwich fluorescence immunoassay. The capture site contains a single MAb specific for the analyte attached to the test disk surface. The analyte binds to the caP.ture antibody and a fluorescein-labelled an~lbody. The epitopes selected are directed at resl~ues 27-40 of the N-terminal region (fluorescem-Iabelled detection Ab) and 191-194 in the C-terminal region beyond the TnC-binding site (streptavidin-Iabelled capture antibody). As the system Uses fresh EDTA anticoagulated whole blood this will minimize steric interference from changes in Ca 2 f concentration. Although the Cte .
rrninu, is less stable, the system uses fresh
Whole blood and samples are stable for up to 4 h.
A~say %CV was 7·4 (0,3 J-Ig/L) to 8·8 (2,38 J-Ig/L)
With diagnostic sensitivity and specificity for AMI of 93% and 94%, respectively.P''i'?"
CONCLUSIONS AND RECOMMENDATJONS ON ASSAY SELECTION
There is a range of assays available. In view of the potential reclassification of the diagnosis of AMI and the role of cTnT and cTnl in diagnosis, risk stratification and therapy, the following recommendations can be made.
• The assay should have a short T AT and be capable for use as a 'stat' assay. • The 97'5th centile of a reference population should be low. ideally less than the functional sensitivity with a %CV of 10 at the 99th centile of the reference population. • The assay should have published data to Support its lise in risk stratification in values between the upper reference limit and the quoted AMI cut-off based on the original WHO criteria. Diagnosis of AMI based on CK-MB (diagnostic equivalence to CK-MB ma " measurement) alone is no longer sufficient. • If a stat lab/PaCT is to be used in addition to the main analytical platform. the results should be similar with identical diagnostic cut-offs, the Analytical Investigations Standing Committee for commissioning the report (and their patience during its preparation).
